Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This study tests whether adding the experimental drug SKB264 to the standard targeted therapy osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 420 adults who have not had prior treatment for advanced dis…

This study tests whether adding the experimental drug SKB264 to the immunotherapy pembrolizumab works better than standard chemotherapy plus pembrolizumab for people with advanced non-squamous lung cancer that lacks the PD-L1 protein. About 432 adults with stage IIIB/IV disease w…

This phase 2 trial tests a new drug called SKB264, given by IV every two weeks, in 20 women with recurrent ovarian epithelial cancer. It also looks at how the antibiotic clarithromycin affects SKB264 levels in the body. The main goals are to see if the drug shrinks tumors and to …

This early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…

This study tests an experimental drug called KL590586, taken as a capsule, in people with advanced solid tumors that have specific RET gene changes. The trial has two phases: Phase I checks safety and the right dose, while Phase II looks at how well the drug shrinks tumors. Up to…

This study tests whether adding the experimental drug SKB264 to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). About 406 participants who have not had …

This phase 2 study tests a new drug called SKB264, alone or with another drug KL-A167, in 175 people with advanced HER2-negative breast cancer that hasn't been treated before. The goal is to see if the combination is safe and can shrink tumors. Participants are split into groups …

This early-stage study tests a new drug called A166 in 120 adults with advanced HER2-positive solid tumors that have spread or cannot be removed by surgery. The main goal is to check safety and find the right dose, while also seeing if the drug shrinks tumors. Participants must h…

This phase 2 trial tests the safety and effectiveness of SKB264, a new drug, in 321 adults with advanced solid tumors, specifically non-small cell lung cancer and nasopharyngeal carcinoma. Participants receive SKB264 alone until the drug stops working or side effects become too s…

This phase 3 trial compares a new drug called A166 to the standard drug T-DM1 in about 365 people with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. Participants must have already been treated with trastuzumab and a taxane…

This phase 3 trial tests whether adding the experimental drug KL-A167 to standard chemotherapy (cisplatin and gemcitabine) helps people with recurrent or metastatic nasopharyngeal carcinoma live longer without their cancer growing. About 295 adults aged 18–75 are participating. T…

This Phase 3 trial tests a new chemotherapy drug called SKB264 against standard chemotherapies in 254 people with advanced triple-negative breast cancer that has worsened after at least two prior treatments. The main goal is to see if SKB264 can delay cancer growth longer than th…

This phase 3 trial tests a new drug called SKB264 against standard chemotherapy in 376 adults with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to targeted therapy. The goal is to see if SKB264 can slow cancer growth better than chemo. …